News from elusys therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 02, 2020, 08:00 ET Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax

Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody (mAb)...

Oct 08, 2020, 12:21 ET Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthrax

Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

Apr 23, 2018, 10:00 ET Elusys Receives Second Delivery Order From U.S. Government for ANTHIM®, its Treatment for Inhalation Anthrax

Elusys Therapeutics, Inc. (Elusys) announced today that it has been awarded a $25.2 million follow-on Delivery Order (DO) by the U.S. Government for...

Oct 10, 2017, 10:00 ET Elusys Delivers First Shipment Of ANTHIM®, Its Treatment For Inhalation Anthrax, To The U.S. Government Strategic National Stockpile

Elusys Therapeutics, Inc. (Elusys) announced today that the company has delivered the first doses of ANTHIM® (obiltoxaximab) Injection, its treatment ...

Jan 24, 2017, 07:30 ET Elusys Receives $16.35 Million For Delivery Of ANTHIM® To U.S. Government

Elusys Therapeutics, Inc. (Elusys) today announced it has received $16.35 million for completing the second delivery of ANTHIM® (obiltoxaximab)...

Dec 20, 2016, 01:14 ET Elusys Therapeutics Announces Publication Of Data Establishing The Adult Human Dose For Its Inhalational Anthrax Antitoxin, ANTHIM® (obiltoxaximab) Injection

Elusys Therapeutics, Inc. (Elusys) today announced that the company published data and analyses used to determine the intravenous adult human dose...

Sep 14, 2016, 10:00 ET Elusys Therapeutics Announces Publication Of Results From Five Clinical Trials With Its Inhalational Anthrax Antitoxin, ANTHIM® (obiltoxaximab) Injection

Elusys Therapeutics, Inc. (Elusys) today announced that the company published data on over 450 healthy adult subjects from five clinical trials used...

Jul 20, 2016, 11:59 ET Elusys Therapeutics Announces That Manuscripts For Its Anthrax Antitoxin, ANTHIM® (obiltoxaximab) Injection, Have Been Accepted For Publication

Elusys Therapeutics, Inc. (Elusys) today announced that two important manuscripts describing animal efficacy of ANTHIM (obiltoxaximab) Injection in...

Mar 21, 2016, 10:04 ET Elusys Therapeutics Receives FDA Approval For ANTHIM® (obiltoxaximab) Injection For The Treatment And Prophylaxis Of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys) today announced that the U.S. Food and Drug Administration (FDA) has approved ANTHIM (obiltoxaximab) Injection,...

Nov 12, 2015, 01:27 ET Elusys Therapeutics Receives First Delivery Order From U.S. Government For Anthim® (obiltoxaximab) For Treatment Of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded its first delivery order under a procurement contract for Anthim...

Oct 06, 2015, 09:30 ET Elusys Awarded Additional $16 Million Under Existing U.S. Government Contract To Complete Development Of Lyophilized Form Of Anthim® (Obiltoxaximab) For Treatment Of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded $16 million of additional funding from the U.S. Government to further advance...

Jun 01, 2015, 11:21 ET U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab)

Elusys Therapeutics, Inc. (Elusys) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and review its Biologics...

Feb 12, 2015, 09:15 ET Elusys Reports Efficacy of Its Anthrax Anti-Toxin in Post-Exposure Prophylaxis in Animal Studies

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data...

Sep 22, 2014, 11:58 ET Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has...

Apr 08, 2014, 09:00 ET Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it...

Mar 10, 2014, 10:00 ET Elusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United...

Feb 05, 2014, 09:59 ET Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, ETI-204, in Adult Volunteers

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has...

Sep 05, 2013, 01:30 ET Elusys Therapeutics Presents Efficacy Results And Other Key Findings On ETI-204 Anthrax Anti-Toxin

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented key findings...

Jul 31, 2013, 10:17 ET Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today released data from...

Sep 13, 2012, 01:54 ET Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been awarded...

Sep 08, 2011, 10:00 ET Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the...

Aug 04, 2010, 10:00 ET Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of...

Jan 04, 2010, 10:00 ET Elusys Receives Contract for up to $143 Million from the U.S. Federal Government to Fund Advanced Development of Anthim(R), a New Treatment for Anthrax

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially totaling up ...